- Home
- NEXN vs EYPT Comparison
NEXN vs EYPT Comparison
Compare NEXN & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- EYPT
- Stock Information
- Founded
- NEXN 2007
- EYPT 1987
- Country
- NEXN Israel
- EYPT United States
- Employees
- NEXN N/A
- EYPT N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- NEXN Technology
- EYPT Industrials
- Exchange
- NEXN Nasdaq
- EYPT Nasdaq
- Market Cap
- NEXN 527.2M
- EYPT 427.9M
- IPO Year
- NEXN 2021
- EYPT 2005
- Fundamental
- Price
- NEXN $8.35
- EYPT $5.42
- Analyst Decision
- NEXN Strong Buy
- EYPT Strong Buy
- Analyst Count
- NEXN 9
- EYPT 8
- Target Price
- NEXN $10.63
- EYPT $25.71
- AVG Volume (30 Days)
- NEXN 416.6K
- EYPT 738.5K
- Earning Date
- NEXN 03-05-2025
- EYPT 03-05-2025
- Dividend Yield
- NEXN N/A
- EYPT N/A
- EPS Growth
- NEXN N/A
- EYPT N/A
- EPS
- NEXN 0.51
- EYPT N/A
- Revenue
- NEXN $365,477,000.00
- EYPT $43,273,000.00
- Revenue This Year
- NEXN $5.43
- EYPT N/A
- Revenue Next Year
- NEXN N/A
- EYPT N/A
- P/E Ratio
- NEXN $14.94
- EYPT N/A
- Revenue Growth
- NEXN 10.09
- EYPT N/A
- 52 Week Low
- NEXN $5.11
- EYPT $5.34
- 52 Week High
- NEXN $11.00
- EYPT $23.65
- Technical
- Relative Strength Index (RSI)
- NEXN 53.83
- EYPT 32.55
- Support Level
- NEXN $7.08
- EYPT $5.87
- Resistance Level
- NEXN $8.11
- EYPT $6.69
- Average True Range (ATR)
- NEXN 0.49
- EYPT 0.43
- MACD
- NEXN 0.12
- EYPT -0.08
- Stochastic Oscillator
- NEXN 89.44
- EYPT 3.52
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.